Document is current
Any future updates will be listed below
-
Authors
Cortes, Jorge E. https://orcid.org/0000-0002-8636-1071
Lang, Fabian https://orcid.org/0000-0003-2890-029X
Rea, Delphine
Hochhaus, Andreas https://orcid.org/0000-0003-0626-0834
Breccia, Massimo https://orcid.org/0000-0003-1163-6162
Goh, Yeow Tee https://orcid.org/0000-0002-7069-0997
Heinrich, Michael C. https://orcid.org/0000-0003-3790-0478
Hughes, Timothy P. https://orcid.org/0000-0002-0910-3730
Janssen, Jeroen J. W. M.
le Coutre, Philipp
Minami, Hironobu
Sasaki, Koji https://orcid.org/0000-0002-9140-0610
DeAngelo, Daniel J. https://orcid.org/0000-0001-7865-2306
Sanchez-Olle, Gessami
Pognan, Nathalie
Cao, Meng https://orcid.org/0000-0002-3338-304X
Hoch, Matthias
Mauro, Michael J. https://orcid.org/0000-0002-2251-4032
-
Funding
Funding for this research was provided by:
Novartis
- License Information
-
More Information
Article History
Received: 14 February 2025
Revised: 6 March 2025
Accepted: 26 March 2025
First Online: 9 April 2025
Competing interests
: JEC: Novartis, Pfizer, and Bristol Myers Squibb: grants, consulting fees. FL: Bristol Myers Squibb, Incyte, and Celgene: consultancy, honoraria; Novartis: consultancy, honoraria, and research funding. DR: Novartis, Pfizer, and Incyte: personal fees. AH: Bristol Myers Squibb, Pfizer: institutional research support; Novartis and Incyte: institutional research support, personal honoraria. MB: Bristol Myers Squibb, Celgene, Pfizer, Incyte, and Novartis: consultancy and honoraria; AbbVie: consultancy. YTG: Pfizer, Johnson & Johnson, Amgen, MSD Pharma, EUSA Pharma, Roche, Bristol Myers Squibb, and AbbVie: honoraria. MCH: Novartis, Deciphera, Theseus, and Blueprint Medicines: consultancy; Deciphera: speakers bureau; Jonathan David Foundation, VA Merit Review Grant (I01BX005358), and NCI R21 grant (R21CA263400): partial salary support. Prior to 2019, MCH held an equity interest in MolecularMD. MCH holds multiple patents on the diagnosis and/or treatment of gastrointestinal stromal tumors; 1 patent on treatment has been licensed by Oregon Health & Science University to Novartis. TPH: Novartis, Bristol Myers Squibb, and Enliven: consultancy, research funding. JJWMJ: Novartis and Bristol Myers Squibb: research funding; Incyte: speakers fee; AbbVie, Novartis, Pfizer, and Incyte: honoraria; AbbVie, Alexion, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen-Cilag, Olympus, Incyte, Sanofi Genzyme, Servier, Jazz, and Takeda: support for Apps for Care and Science nonprofit foundation, of which JJWMJ is president. PlC: Pfizer, Novartis, and Incyte: honoraria. HM: Chugai Pharma, Daiichi Sankyo, Eisai, Genmab, Guardant Health, Kyowa Kirin, Lilly Japan, Meiji Seika Kaisha, Miyarisan Pharmaceutical, Novartis, Otsuka Pharmaceutical, Pfizer, Shionogi, Rakuten Medical, Taiho Pharmaceutical, and Takeda: honoraria; Asahi Kasei Pharma, Chugai Pharma, Dainippon Sumitomo Pharma, Kyowa Kirin, Otsuka Pharmaceutical, Taiho Pharmaceutical, Nihonkayaku, and Teijin Pharma: research funding. KS: Novartis: research funding, honoraria. DJD: AbbVie, Novartis, Blueprint, and GlycoMimetics: grants; AbbVie, Novartis, Blueprint, and GlycoMimetics: research funding; AbbVie, Amgen, Autolus, Blueprint, Forty-Seven, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda: consulting; AbbVie, Amgen, Autolus, Blueprint, Forty-Seven, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda: personal fees. GSO, NP, and MC are employees of Novartis. MH is an employee and shareholder of Novartis. MJM: Bristol Myers Squibb, Takeda, and Pfizer: personal fees.
